BZYR Stock Overview

Engages in the research and development of antineoplaston drugs for the treatment of various cancers. More details

BZYR fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Risk Analysis

Negative shareholders equity

Has less than 1 year of cash runway

Makes less than USD$1m in revenue ($0)

Does not have a meaningful market cap ($5M)

+ 1 more risk

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Burzynski Research Institute, Inc. Competitors

Alzamend Neuro

NasdaqCM:ALZN

US$2.4m

Dermata Therapeutics

NasdaqCM:DRMA

US$4.3m

Azitra

NYSEAM:AZTR

US$4.2m

Sonnet BioTherapeutics Holdings

NasdaqCM:SONN

US$3.8m

Price History & Performance

Summary of share price highs, lows and changes for Burzynski Research Institute
Historical stock prices
Current Share Price	US$0.04
52 Week High	US$0.077
52 Week Low	US$0.03
Beta	2.03
1 Month Change	-10.29%
3 Month Change	-19.26%
1 Year Change	-8.25%
3 Year Change	169.13%
5 Year Change	236.42%
Change since IPO	34.57%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	BZYR	US Biotechs	US Market
7D	26.9%	3.7%	5.3%
1Y	-8.3%	-14.2%	11.9%

Return vs Industry: BZYR exceeded the US Biotechs industry which returned -16.2% over the past year.

Return vs Market: BZYR underperformed the US Market which returned 11.2% over the past year.

Price Volatility

Is BZYR's price volatile compared to industry and market?
BZYR volatility
BZYR Average Weekly Movement	n/a
Biotechs Industry Average Movement	11.9%
Market Average Movement	8.1%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	4.1%

Stable Share Price: BZYR's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine BZYR's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1984	n/a	Stanislaw Burzynski	propcitweb.ddns.net:83

Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services.

Burzynski Research Institute, Inc. Fundamentals Summary

How do Burzynski Research Institute's earnings and revenue compare to its market cap?
BZYR fundamental statistics
Market cap	US$5.31m
Earnings (TTM)	-US$1.46m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-3.6x

P/E Ratio

Is BZYR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BZYR income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$1.46m
Earnings	-US$1.46m

Last Reported Earnings

Nov 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.011
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did BZYR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/17 14:53
End of Day Share Price	2025/05/14 00:00
Earnings	2024/11/30
Annual Earnings	2024/02/29

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Burzynski Research Institute, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.